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Abstract: The effect of the anti-hypertensive drug eprosartan on metabolic parameters is currently not extensively docu-
mented. We evaluated the effect of eprosartan on parameters involved in atherogenesis, oxidative stress and clotting activ-
ity. This open-label unblinded intervention study included 40 adult patients with essential hypertension taking eprosartan. 
Eprosartan significantly reduced by 8% (p<0.001) the systolic and by 13% (p<0.001) the diastolic blood pressure, and in-
creased by 24% the time needed to produce oxidative by-products (p=0.001), a marker of oxidative stress. In contrast, ep-
rosartan did not alter 8-isoprostane (8-epiPGF2a) levels, another marker of oxidative stress. Additionally, eprosartan re-
duced by 14% aspartate aminotransferase and by 21% then alanine aminotransferase activity, while it had a neutral effect 
on the lipid profile and apolipoprotein levels and did not influence glucose homeostasis, creatinine and uric acid levels. 
Eprosartan did not affect the clotting/fibrinolytic status (estimated by plasminogen activator inhibitor 1, tissue plasmino-
gen activator and a2 antiplasmin levels), or the enzymatic activity of the lipoprotein associated phospholipase A2 (Lp-
PLA2) and paraoxonase 1 (PON1). In conclusion, eprosartan should be mainly considered as an anti-hypertensive agent 
with neutral effects on most of the metabolic parameters in hypertensive patients. 
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INTRODUCTION 
  Eprosartan is an angiotensin II receptor antagonist ap-
proved for the treatment of essential hypertension with par-
ticular benefit for the secondary prevention of stroke beyond 
the absolute level of blood pressure reduction [1,2]. How-
ever, the effect of eprosartan on various metabolic parame-
ters is currently not extensively documented. Any such ef-
fects may be useful, as vascular damage is considered to be a 
sequel of various underlying mechanisms that are present in 
hypertensive patients. Some of these mechanisms involve 
alterations in clotting/fibrinolytic activity, the oxidative 
damage of vessels and the inflammatory process [3,4]. 
Moreover, the lipid profile and glucose homeostasis repre-
sent additional well-known risk factors for the development 
of vascular disease in hypertensive patients [5].  
  Additional actions that could differentiate some of the 
anti-hypertensive drugs, even within the same class, may 
affect the evolution of vascular damage. Therefore, we as-
sessed whether eprosartan exerts additional effects on pa-
rameters involved in atherogenesis, oxidative stress and clot-
ting activity, beyond its antihypertensive action. 
PATIENTS AND METHODS 
Participants 
  This open-label intervention study was conducted in pa-
tients attending the Metabolism and Lipid Clinic of the Uni-
versity Hospital in Ioannina, Greece. We included adult   
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patients with essential hypertension defined as systolic blood 
pressure (SBP) > 140 mmHg and/or diastolic blood pressure 
(DBP) > 90 mmHg. All individuals were newly diagnosed as 
hypertensives. Patients with liver or renal disease (serum 
aminotransferase activity greater than 3-fold (e.g. 120 IU/l), 
serum creatinine levels > 1.5 mg/dl, hypothyroidism (thyroid 
stimulating hormone > 5 mIU/ml), heavy alcohol consump-
tion (>3 drinks per day) or patients receiving drugs that 
could affect lipid metabolism, renal or hepatic function, as 
well as any drug that could affect the parameters examined 
in the study were excluded. In particular, the diabetic pa-
tients who were on oral anti-diabetic medications did not 
make any change in the drugs or their doses during the study 
period.  
  The Ethical Committee approved the study and all par-
ticipants gave their formal consent. All patients (n=43) were 
initially advised regarding lifestyle modification and eprosar-
tan 600 mg once daily was administered in those patients 
who remained hypertensive after a period of 6 weeks (n=40). 
Measurements 
  All laboratory determinations were carried out after an 
overnight fast at the beginning of the study and 12 weeks 
following eprosartan treatment. Serum levels of total choles-
terol (TC), high density lipoprotein cholesterol (HDL-C), 
triglycerides, glucose, transaminases, creatinine and uric acid 
were determined by standard methods using an Olympus 
AU600 Clinical Chemistry analyzer (Olympus Diagnostica, 
Hamburg, Germany). Serum apolipoprotein (Apo) A1, B and 
E levels were measured using a Behring Nephelometer 
BN100 and reagents from Dade Behring Holding GmbH 
(Liederbach, Germany). Serum insulin levels were measured 
by an AxSYM insulin assay microparticle enzyme immuno-Effect of Eprosartan on Metabolic Parameters  The Open Cardiovascular Medicine Journal, 2007, Volume 1    23 
assay on an AxSYM analyzer (Abbott Diagnostics). Fibrino-
gen, a2-antiplasmin, and platelet activator inhibitor-1 (PAI-
1) were measured by Dade Behring BCS analyzer and tissue 
plasminogen activator (tPA) by ELISA. Low density lipo-
protein cholesterol (LDL-C) was calculated by the Friede-
wald formula [TC – HDL-C – (TRG /5)], insulin sensitivity 
with the homeostasis model assessment (HOMA) index 
([fasting insulin (mU/L) X fasting glucose (mg/dL)] / 405), 
fractional excretion of uric acid with (urinary uric acid X 
serum creatinine x 100) / (serum uric acid X urinary creatin-
ine), and body mass index (BMI) as (kg) / height
2 (m).  
  For the estimation of oxidative stress we measured the 
plasma levels of 8-isoprostane (8-epiPGF2a), as well as the 
susceptibility to oxidation of total serum lipids. The plasma 
levels of 8-epiPGF2a were determined by means of a com-
petitive ELISA using a commercially available kit (Cayman 
Chemicals, Ann Arbor, MI), as we recently described [6]. 
Oxidation of freshly prepared serum was performed at 37ºC 
in the presence of 100 μM CuSO4. The kinetics of serum 
oxidation was determined by monitoring the increase in the 
245 nm absorbance, every 10 min for 6 h. The lag time, 
which reflects the resistance of serum lipids to copper-
induced oxidation, was calculated as previously described 
[7,8].  
  Serum paraoxonase 1 (PON1) activity was determined 
using paraoxon as a substrate in the presence of 2 mM Ca
+2 
in 100 mM tris-HCL buffer [9]. Lipoprotein-associated phos-
pholipase A2  (Lp-PLA2) activity in total plasma was 
determined by the trichloroacetic acid precipitation proce-
dure using 1-0-hexadecyl-2-[
3H-acetyl]-sn-glycero-3-
phosphocholine ([
3H]-PAF) (100 μM final concentration) as 
a substrate [10]. Lp-PLA2 activity was expressed as nmol of 
platelet activating factor (PAF) degraded per min per ml of 
plasma. 
Statistical Analysis 
  Descriptive statistics for continuous variables expressed 
as means with standard deviation (SD), or median with mini-
mum/maximum range were used. Continuous variables were 
tested for lack of normality with the Kolmogorov–Smirnov 
test and, accordingly, comparison of the mean values before 
and after eprosartan treatment was performed with the paired 
t-test, while comparison of the median values was assessed 
with the non-parametric Wilcoxon signed rank test. 
  Statistical analysis was performed using Statistica ver-
sion 6.0 (StatSoft Inc, Tulsa, Okla). Significance was defined 
as p<0.05.  
RESULTS 
  Forty Caucasians (19 females) with essential hyperten-
sion were enrolled in the study. Their mean age was 57 
years. Most of them were overweight, 17 had metabolic syn-
drome according to the updated AHA NHLBI statement (de-
fined as 3 or more of the following: waist circumference > 
102 cm in men and > 88 cm in women, blood pressure  
130/85 mmHg, triglycerides > 150 mg/dl, HDL-C < 40 
mg/dl in men and < 50 mg/dl in women, and fasting glucose 
 100 mg/dl), 8 had type 2 diabetes and 18 were smokers 
(Table 1).  
 
Table 1.  Baseline Characteristics of Study Patients 
N (females/males)  40 (19/21) 
Age (years)  57 ± 11  
Weight (kg)  77 ± 15 
BMI (kg/m
2)  28.6 ± 5.2 
Smokers  18 
Metabolic syndrome  17 
Diabetes  8 
BMI: body mass index. 
Mean values ± standard deviation. 
 
  Eprosartan reduced SBP by 8% (p<0.001) and DBP by 
13% (p<0.001), while it had a neutral effect on the lipid pro-
file and apolipoprotein levels (Table 2). 
  Eprosartan did not affect plasma 8-epiPGF2a levels, 
whereas it significantly increased by 24% the lag time of 
total serum oxidation (145 ± 54 min vs 180 ± 58 min, 
p=0.001) (Table 2). Eprosartan reduced by 14% the aspartate 
aminotransferase (form 21 to 18 U/L, p=0.04) and by 21% 
the alanine aminotransferase (from 24 to 19 U/L, p=0.05) 
activity (Table 2). 
  The administration of eprosartan had no influence on 
glucose homeostasis, as well as on creatinine and uric acid 
levels (Table 2). In addition, eprosartan did not affect clot-
ting or fibrinolytic activity as this was estimated by PAI-1, 
tPA and a2-antiplasmin (Table 2). The enzymatic activity of 
Lp-PLA2 and PON1 were not altered significantly following 
eprosartan treatment (Table 2). 
DISCUSSION 
  We found that eprosartan reduced BP levels, but its ef-
fects beyond its anti-hypertensive action were limited. 
Across a wide range of markers related to atherogenesis, 
such as lipid metabolism, glucose homeostasis, clot-
ting/fibrinolytic process, oxidative stress, and inflammatory 
mediators for vascular damage, the only additional finding 
following eprosartan therapy was the reduction in the sus-
ceptibility of serum lipids to oxidation as estimated by the 
increase in lag time, while 8-epiPGF2a, the other marker of 
oxidative stress, remained unaltered. Thus, any beneficial 
effect of eprosartan on morbidity/mortality should be mainly 
attributed to its anti-hypertensive action.  
  Atherogenesis is considered to be a complex phenome-
non implicating vascular oxidative stress, inflammatory 
pathways and abnormalities in the coagulation/fibrinolysis 
equilibrium [11]. We estimated the oxidative stress by meas-
urement of 8-epiPGF2a levels, as well as the lag time for the 
copper-induced oxidation of lipids. 8-epiPGF2a is the most 
abundant isomer of the F2-isoprostanes, which are isomers 
of the F2a prostaglandin produced by nonenzymatic 
peroxidation of arachidonic acid. 8-epiPGF2a is considered 
to be a marker of oxidative stress, especially of endogenous 
lipid peroxidation [12-15]. Interestingly, eprosartan 
increased by 24% the time needed to produce oxidative by-
products, while 8-epiPGF2a levels remained unchanged. The 24    The Open Cardiovascular Medicine Journal, 2007, Volume 1  Rizos et al. 
Table 2.  Serum Metabolic Parameters at Baseline and 12 Weeks Following Eprosartan Treatment 
 Baseline*  12  weeks*  P 
SBP (mmHg)   154 ± 10  141 ± 12  <0.001 
DBP (mmHg)   96 ± 8  84 ± 9  <0.001 
TC (mg/dL)  212 ± 32  219 ± 33  NS 
Triglycerides (mg/dL)  115 ± 50  113 ± 39  NS 
HDL-C (mg/dL)  53 ± 8  55 ± 10  NS 
LDL-C (mg/dL)  134 ± 24  142 ± 28  NS 
ApoA1 (mg/dL)  145 ± 20  153 ± 25  NS 
ApoB (mg/dL)  86 ± 22  95 ± 20  NS 
ApoE (mg/dL)  3.8 ± 0.7  3.9 ± 1.4  NS 
Lp(a) (mg/dL)  10 (8-72)  10 (8-11)  NS 
Glucose (mg/dL)  94 ± 12  96 ± 13  NS 
Insulin (mU/L)  8.8 ± 3.4  9.9 ± 5.5  NS 
HOMA index  2.2 ± 0.9  2.6 ± 1.5  NS 
AST (U/L)  21 ± 4.6  18 ± 4.6  0.04 
ALT (U/L)  24 ± 8  19 ± 8  0.05 
Creatinine (mg/dL)  0.86 ± 0.11  0.87 ± 0.12  NS 
Uric acid (mg/dL)  4.5 ± 1.5  4.7 ± 1.4  NS 
FE uric acid (%)  13 ± 6  10 ± 3  NS 
Fibrinogen (mg/dL)  343 ± 85  347 ± 98  NS 
PAI-1 (U/L)  3.4 ± 2.6  3.0 ± 1.3  NS 
tPA (ng/mL)  7.1 ± 3.2  8.6 ± 4.8  NS 
A2-antiplasmin (%)  100 ± 9  101 ± 17  NS 
8-epiPGF2a (pg/mL)  61 ± 20  67 ± 24  NS 
Lag time (min)  145 ± 54  180 ± 58  0.001 
PON1 (U/L)  60 (20-175)  59 (27-201)  NS 
Lp-PLA2 (nmol/mL/min)  29 ± 8  34 ± 16  NS 
SBP: systolic blood pressure; DBP: diastolic blood pressure; TC: total cholesterol; LDL-C: low density lipoprotein cholesterol; HDL-C: high density lipoprotein cholesterol; ApoA1: 
apolipoprotein A1; ApoB: apolipoprotein B; ApoE: apolipoprotein E; Lp(a): lipoprotein (a); HOMA: homeostasis model assessment index; AST: aspartate aminotransferase; ALT: 
alanine aminotransferase; FE: fractional excretion; PAI-1: platelet activator inhibitor-1; tPA: tissue plasminogen activator; 8-epiPGF2a: 8-isoprostanes; PON1: paraoxonase 1; Lp-
PLA2: lipoprotein-associated phospholipase A2. 
*Mean values ± standard deviation or median with min/max range. 
**NS: not significant. 
increase of the lag time for LDL oxidation has been previ-
ously reported in patients with mild to moderate essential 
hypertension, and was attributed to the modulation of 
NADH/NADPH oxidase, which counteracts superoxide pro-
duction [16].  
  Eprosartan had no effect on lipid profile, as well as on 
PON1 and Lp-PLA2 that are determinants of lipoprotein 
function and therefore are involved in atherosclerosis. The 
neutral effect of eprosartan on lipid profile has been previ-
ously reported [17], and was also evident in diabetic patients 
[18]. PON1 and Lp-PLA2 are enzymes related to the in-
flammatory mechanisms that take part in atherogenesis. 
PON1 is an esterase that is exclusively associated with HDL 
in plasma and catalyses the hydrolysis of phospholipid hy-
droperoxides and cholesteryl ester hydroperoxides, which are 
formed during LDL oxidation. Thus, PON1 may play an 
important role in the anti-atherogenic activity of HDL. In 
contrast, Lp-PLA2, an enzyme mainly associated with LDL, 
is currently related to the inflammatory mechanisms of the 
atherogenic process. Lp-PLA2 exhibits a Ca
+2-independent 
phospholipase A2 activity and catalyses the hydrolysis of the 
ester bond at the sn-2 position of the proinflammatory phos-Effect of Eprosartan on Metabolic Parameters  The Open Cardiovascular Medicine Journal, 2007, Volume 1    25 
pholipid mediator PAF. Lp-PLA2 also degrades oxidatively 
fragmented phospholipids, which are formed during the oxi-
dative modification of LDL and are implicated in athero-
genesis [19,20]. Neither PON1 nor Lp-PLA2 activity were 
significantly altered after eprosartan therapy, in accordance 
with the neutral effect of other anti-hypertensive agents on 
these enzymes [21].  
  On the other hand, the decrease of transaminase activity 
following eprosartan administration was consistent with a 
similar effect following losartan treatment [22]. These find-
ings should be interpreted with caution, because a liver bi-
opsy was not performed in any of our patients to diagnose 
non-alcoholic fatty liver disease (NAFLD). However, this 
reduction in liver transaminases may represent a beneficial 
effect of angiotensin receptor blockers on NAFLD. 
  Eprosartan had no influence on glucose homeostasis, as 
was evident from the measurement of glucose, insulin and 
HOMA index. Consistent with our results, in experimental 
studies with animals eprosartan failed to induce peroxisome-
proliferator–activated receptor (PPAR)  activity and accord-
ingly failed to demonstrate insulin-sensitizing/antidiabetic 
effects [23,24]. In humans, eprosartan also has been reported 
to exert a neutral effect on glucose and insulin levels [17], 
even in diabetic patients [18].  
  Eprosartan had a neutral effect on creatinine and uric acid 
levels, as previously reported [25-27].  
  Finally, eprosartan did not interfere with the coagula-
tion/fibrinolysis status, although in one report eprosartan 
seemed to favourably affect these variables [28].  
  Currently, the anti-hypertensive potency of a drug is con-
sidered to be the principal factor that lowers morbid-
ity/mortality and guidelines focus on BP levels as the main 
target of therapy. In this respect, eprosartan lowered both the 
SBP and DBP. In contrast, eprosartan had a neutral effect on 
various metabolic parameters related to the development of 
vascular disease. The novel findings that eprosartan in-
creased the time needed to produce oxidative by-products 
and the effect of eprosartan on liver transaminases requires 
confirmation from larger studies, focusing specifically on 
eprosartan. This is because there are differences in the prop-
erties of the drugs, even in the same class, as was evident 
from the PPAR  agonist activity of telmisartan and the uri-
cosuric activity of losartan [29].  
  In conclusion, based on our findings, eprosartan should 
be mainly considered as an anti-hypertensive medication 
with neutral effects on most of the underlying metabolic pa-
rameters in hypertensive patients. 
REFERENCES 
[1]  Robins GW, Scott LJ. Eprosartan: a review of its use in the man-
agement of hypertension. Drugs 2005; 65: 2355-77.  
[2]  Schrader J, Luders S, Kulschewski A, et al. Morbidity and mortal-
ity after stroke, eprosartan compared with nitrendipine for secon-
dary prevention. Principal results of a prospective randomized con-
trolled study (MOSES). Stroke 2005; 36: 1218-26. 
[3]  Koh KK, Han SH, Quon MJ. Inflammatory markers and the meta-
bolic syndrome: insights from therapeutic interventions. J Am Coll 
Cardiol 2005; 46(11): 1978-85. 
[4]  Paoletti R, Gotto AM Jr, Hajjar DP. Inflammation in atherosclero-
sis and implications for therapy. Circulation 2004; 109(23 Suppl 1): 
11120-6. 
[5]  Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. 
Lancet 2005; 365: 1415-28. 
[6]  Dounousi E, Papavasiliou E, Makedou A, et al. Oxidative stress is 
progressively enhanced with advancing stages of CKD. Am J Kid-
ney Dis 2006; 48: 752-60. 
[7]  Mellou F, Lazari D, Skaltsa H, Tselepis AD, Kolisis FN, Stamatis 
H. Biocatalytic preparation of acylated derivatives of flavonoid 
glycosides enhances their antioxidant and antimicrobial activity. J 
Biotechnol 2005; 116: 295-303. 
[8]  Schnitzer E, Pinchuk I, Bor A, Fainaru M, Samuni AM, Lichten-
berg D. Lipid oxidation in unfractionated serum and plasma. Chem. 
Phys. Lipids 1998; 92: 151-70. 
[9]  Tsimihodimos V, Karabina SA, Tambaki AP, et al. Atorvastatin 
preferentially reduces LDL-associated platelet-activating factor 
acetylhydrolase activity in dyslipidemias of type IIA and type IIB. 
Arterioscler Thromb Vasc Biol 2002; 22: 306-11.  
[10]  Tselepis AD, Dentan C, Karabina SA, Chapman MJ, Ninio E. 
PAF-degrading acetylhydrolase is preferentially associated with 
dense LDL and VLDL-1 in human plasma: catalytic characteristics 
and relation to the monocyte-derived enzyme. Arterioscler Thromb 
Vasc Biol 1995; 15: 1764-73. 
[11]  Hansson GK. Inflammation, atherosclerosis, and coronary artery 
disease. N Engl J Med 2005; 352: 1685-95. 
[12]  Tsimikas S. Oxidative biomarkers in the diagnosis and prognosis of 
cardiovascular disease. Am J Cardiol 2006; 98(11A): 9P-17P. 
[13]  Spirou A, Rizos E, Liberopoulos EN, et al. Effect of barnidipine on 
blood pressure and serum metabolic parameters in patients with es-
sential hypertension: a pilot study. J Cardiovasc Pharmacol Ther 
2006; 11: 256-61. 
[14]  Morrow JD, Hill KE, Burk RF, Nammour TM, Badr KF, Roberts 
LJ. A series of PGF2-like compounds are produced in vivo in hu-
mans by a noncycloxoxygenase, free radical-catalyzed mechanism. 
Proc Natl Acad Sci U S A 1990; 87: 9383-7.  
[15]  Lim PS, ChangYM, Thien LM, et al. 8-Iso-prostaglandin F2alpha 
as a useful clinical biomarker of oxidative stress in ESRD patients. 
Blood Purif 2002; 20: 537-42.  
[16]  Rahman ST, Lauten WB, Khan QA, Navalkar S, Parthasarathy S, 
Khan BV. Effects of eprosartan versus hydrochlorothiazide on 
markers of vascular oxidation and inflammation and blood pressure 
(Renin-Angiotensin system antagonists, oxidation, and inflamma-
tion). Am J Cardiol 2002; 89: 686–90. 
[17]  Levine B. Eprosartan provides safe and effective long-term main-
tenance of blood pressure control in patients with mild to moderate 
essential hypertension. Curr Med Res Opin 2001; 17: 8-17. 
[18]  Derosa G, Ragonesi PD, Mugellini A, Ciccarelli L, Fogari R. Ef-
fects of telmisartan compared with eprosartan on blood pressure 
control, glucose metabolism and lipid profile in hypertensive, type 
2 diabetic patients: a randomized, double-blind, placebo-controlled 
12-month study. Hypertens Res 2004; 27: 457–64. 
[19]  Rizos E, Tambaki AP, Gazi I, Tselepis AD, Elisaf M. Lipoprotein-
associated PAF-acetylhydrolase activity in subjects with the meta-
bolic syndrome. Prostaglandins Leukot Essent Fatty Acids 2005; 
72: 203-9. 
[20]  Tselepis AD, Chapman JM. Inflammation, bioactive lipids and 
atherosclerosis: potential roles of a lipoprotein-associated phos-
pholipase A2, platelet activating factor-acetylhydrolase. Athero-
scler Suppl 2002; 3: 57-68. 
[21]  Tambaki AP, Rizos E, Tsimihodimos V, Tselepis AD, Elisaf M. 
Effects of antihypertensive and hypolipidemic drugs on plasma and 
high-density lipoprotein-associated platelet activating factor-
acetylhydrolase activity. J Cardiovasc Pharmacol Ther 2004; 9: 91-
5. 
[22]  Yokohama S, Yoneda M, Haneda M, et al. Therapeutic efficacy of 
an angiotensin II receptor antagonist in patients with nonalcoholic 
steatohepatitis. Hepatology 2004; 40: 1222-5. 
[23]  Schupp M, Janke J, Clasen R, Unger T, Kintscher U. Angiotensin 
type 1 receptor blockers Induce peroxisome proliferators activated 
receptor- ctivity. Circulation 2004; 109: 2054-7. 
[24]  Schupp M, Clemenz M, Gineste R, et al. Molecular characteriza-
tion of new selective peroxisome proliferators activated receptor  
modulators with angiotensin receptor blocking activity. Diabetes 
2005; 54: 3442-52. 
[25]  Puig JG, Torres R, Ruilope LM. AT1 blockers and uric acid me-
tabolism: are there relevant differences? J Hypertens Suppl 2002; 
20(5): S29-31.  26    The Open Cardiovascular Medicine Journal, 2007, Volume 1  Rizos et al. 
[26]  Ilson BE, Martin DE, Boike SC, Jorkasky DK. The effects of epro-
sartan, an angiotensin II AT1 receptor antagonist, on uric acid ex-
cretion in patients with mild to moderate essential hypertension. J 
Clin Pharmacol 1998; 38(5): 437-41.  
[27]  Puig JG, Mateos F, Buno A, Ortega R, Rodriguez F, Dal-Re R. 
Effect of eprosartan and losartan on uric acid metabolism in pa-
tients with essential hypertension. J Hypertens 1999; 17(7): 1033-9.  
[28]  Makris TK, Stavroulakis G, Papadopoulos DP, et al. Eprosartan 
effect on fibrinolytic/hemostatic variables in arterial hypertension: 
a comparative study to losartan. Drugs Exp Clin Res 2004; 30: 125-
32.  
[29]  Karagiannis A, Mikhailidis DP, Athyros VG, et al. The role of 
renin-angiotensin system inhibition in the treatment of hyperten-
sion in metabolic syndrome: are all the angiotensin receptor block-
ers equal? Expert Opin Ther Targets 2007; 11(2): 191-205. 
 
 
 
Received: September 26, 2007  Revised: October 01, 2007  Accepted: October 02, 2007 
 